Kymera Therapeutics Inc. (KYMR) delivered the kind of clinical trial results that biotechs dream about on Monday: data showing their experimental oral pill performed as well as, or sometimes better than, established injectable drugs. The market noticed, sending shares up over 42% to fresh highs.

The company released Phase 1b results for KT-621, an oral medication designed to treat atopic dermatitis, commonly known as eczema. What makes this noteworthy is the comparison point. Kymera's oral pill is going head-to-head with injectable biologics that currently dominate the market, and the early data suggests it's holding its own.

KT-621 works by degrading STAT6, a protein involved in the immune signaling pathways that drive allergic inflammation. It's a novel approach to blocking the IL-4/IL-13 pathways, which are central players in atopic dermatitis and other allergic diseases. Instead of injecting antibodies that block these pathways from the outside, Kymera's drug gets the body to break down a key protein in the pathway itself.

"The BroADen study results exceeded our highest expectations and provide a powerful additional validation of our industry-leading STAT6 degrader program," said Nello Mainolfi, Founder, President, and CEO of Kymera Therapeutics.

Mainolfi went further, noting that "the results were in line with, or in some cases numerically exceeded, published data for dupilumab at week 4, and we believe further reinforce Kymera's pioneering expertise in developing transformative oral small molecules with the potential for the activity and safety of injectable biologics."

Dupixent (dupilumab) is the benchmark here. It's a blockbuster injectable drug from Sanofi SA (SNY) and Regeneron Pharmaceuticals Inc. (REGN) that's become a standard treatment for moderate to severe eczema. If an oral pill can match that performance, it's a big deal for patient convenience and potentially market share.

The Data That Moved Markets

KT-621 demonstrated deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested in the trial. By Day 29, median STAT6 degradation in blood hit 98% at both dose levels. That's about as complete as you can get.

Even more impressive, the drug worked in skin lesions, where STAT6 levels were twice as high compared to healthy volunteers. KT-621 achieved median degradation of 94% at both doses, with some patients seeing STAT6 levels drop below measurable limits.

Inflammation Markers and Clinical Symptoms Improve

The drug achieved strong reductions in Type 2 inflammation biomarkers in blood, including TARC (Thymus and Activation-Regulated Chemokine), a validated marker of Type 2 inflammation. The reductions were associated with baseline TARC levels, consistent with patterns seen in dupilumab studies across multiple diseases.

For FeNO (Fractional Exhaled Nitric Oxide), a validated biomarker of Type 2 lung inflammation in asthma patients, KT-621 achieved median reductions at Day 29 of 25% and 33% in the 100 mg and 200 mg dose groups, respectively.

The clinical endpoints showed encouraging results as well. Patients saw a mean 63% reduction in EASI (Eczema Area and Severity Index) scores and a mean 40% reduction in peak pruritus, the medical term for itching. For eczema sufferers, reducing itch is often as important as clearing visible symptoms.

KT-621 was well-tolerated with a favorable safety profile consistent with earlier Phase 1a results in healthy volunteers, which matters enormously for a drug that patients might take long-term.

What's Next for Kymera

The company's Phase 2b trial, BROADEN2, is already underway in moderate to severe atopic dermatitis patients, with dosing commenced. Results are expected by mid-2027, which will provide a much larger dataset to see if these early results hold up.

Kymera also plans to start the BREADTH Phase 2b trial in asthma patients in the first quarter of 2026, expanding the potential applications of its STAT6 degrader approach.

Shares closed at $94.70, up 42.15% on Monday, marking a new 52-week high for the stock. Investors are clearly betting that an oral alternative to injectable biologics could capture significant market share if later-stage trials confirm these early results.